Promising cancer combo study pulled before it even started
NCT ID NCT04031872
First seen Oct 31, 2025 · Last updated May 21, 2026 · Updated 23 times
Summary
This study aimed to see if adding a new drug (LY3200882) to a standard chemotherapy (capecitabine) could help people with advanced colorectal cancer that no longer responded to treatment. It was designed for patients whose tumors had a specific genetic signature. However, the study was withdrawn before any participants were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.